

Bertrand Rochat

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/880261/bertrand-rochat-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

893
citations

17
h-index

29
g-index

30
ext. papers

1,006
ext. citations

3.6
avg, IF

4.7
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 27 | Robust and sensitive peptidomics workflow for plasma based on specific extraction, lipid removal, capillary LC setup and multinozzle ESI emitter. <i>Talanta</i> , 2021 , 223, 121617 | 6.2 | 1 |
| 26 | Quantitative and Qualitative LC-High-Resolution MS: The Technological and Biological Reasons for a Shift of Paradigm 2019 , | | 4 |
| 25 | LC-HRMS Metabolomics for Untargeted Diagnostic Screening in Clinical Laboratories: A Feasibility Study. <i>Metabolites</i> , 2018 , 8, | 5.6 | 8 |
| 24 | Fully-automated systems and the need for global approaches should exhort clinical labs to reinvent routine MS analysis?. <i>Bioanalysis</i> , 2018 , 10, 1129-1141 | 2.1 | 3 |
| 23 | Proposed Confidence Scale and ID Score in the Identification of Known-Unknown Compounds Using High Resolution MS Data. <i>Journal of the American Society for Mass Spectrometry</i> , 2017 , 28, 709-723 | 3.5 | 40 |
| 22 | Quantitative performance of a quadrupole-orbitrap-MS in targeted LC-MS determinations of small molecules. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 124, 48-56 | 3.5 | 47 |
| 21 | Validation of the Mass-Extraction-Window for Quantitative Methods Using Liquid Chromatography High Resolution Mass Spectrometry. <i>Analytical Chemistry</i> , 2016 , 88, 3264-71 | 7.8 | 28 |
| 20 | From targeted quantification to untargeted metabolomics: Why LC-high-resolution-MS will become a key instrument in clinical labs. <i>TrAC - Trends in Analytical Chemistry</i> , 2016 , 84, 151-164 | 14.6 | 52 |
| 19 | Improved investigations in drug safety by more in-depth individual pharmacokinetics using high-resolution mass spectrometry. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 141-6 | 3.2 | 2 |
| 18 | Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 2627-40 | 4.4 | 29 |
| 17 | A Close Look at the Fate of Compounds we are Exposed to. <i>Chimia</i> , 2014 , 68, 818 | 1.3 | 1 |
| 16 | Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance. <i>PLoS ONE</i> , 2014 , 9, e95532 | 3.7 | 19 |
| 15 | SIMPLE MEASUREMENT OF TESTOSTERONE IN MALE SALIVA SAMPLES USING DISPERSIVE LIQUID-LIQUID MICROEXTRACTION FOLLOWED BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY DETECTION. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2014 , 37, 1278-1286 | 1.3 | 6 |
| 14 | Analysis and quantification of vitamin D metabolites in serum by ultra-performance liquid chromatography coupled to tandem mass spectrometry and high-resolution mass spectrometry--a method comparison and validation. <i>Rapid Communications in Mass Spectrometry</i> , 2013 , 27, 200-6 | 2.2 | 55 |
| 13 | Validation of hepcidin quantification in plasma using LC-HRMS and discovery of a new hepcidin isoform. <i>Bioanalysis</i> , 2013 , 5, 2509-20 | 2.1 | 28 |
| 12 | The future key role of LC-high-resolution-MS analyses in clinical laboratories: a focus on quantification. <i>Bioanalysis</i> , 2012 , 4, 2939-58 | 2.1 | 40 |
| 11 | Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. <i>Rapid Communications in Mass Spectrometry</i> , 2012 , 26, 499-509 | 2.2 | 107 |

| | | | |
|----|---|-----|----|
| 10 | Generic approach for the sensitive absolute quantification of large undigested peptides in plasma using a particular liquid chromatography-mass spectrometry setup. <i>Journal of Chromatography A</i> , 2011 , 1218, 8536-43 | 4.5 | 13 |
| 9 | Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5074-81 | 5.9 | 17 |
| 8 | Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5303-15 | 5.9 | 97 |
| 7 | Comparison between a linear ion trap and a triple quadrupole MS in the sensitive detection of large peptides at femtomole amounts on column. <i>Journal of Separation Science</i> , 2010 , 33, 2478-88 | 3.4 | 18 |
| 6 | Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2008 , 43, 736-52 | 2.2 | 43 |
| 5 | In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. <i>Biopharmaceutics and Drug Disposition</i> , 2008 , 29, 103-18 | 1.7 | 22 |
| 4 | Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples. <i>Journal of Mass Spectrometry</i> , 2007 , 42, 440-9 | 2.2 | 17 |
| 3 | Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers. <i>Journal of Mass Spectrometry</i> , 2006 , 41, 390-404 | 2.2 | 46 |
| 2 | Ritonavir-Boosted Atazanavir-Lopinavir Combination: A Pharmacokinetic Interaction Study of Total, Unbound Plasma and Cellular Exposures. <i>Antiviral Therapy</i> , 2006 , 11, 53-62 | 1.6 | 17 |
| 1 | Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 349-66 | 6.2 | 93 |